COVID-19 related adult multisystem inflammatory disease

Also Known As:

adult multisystem inflammatory disease, COVID-19 related; COVID-19-associated multi-system inflammatory syndrome in adults; COVID-19-associated multisystem inflammatory syndrome in adults; MIS-A; MIS-A associated with COVID-19; MISA associated with COVID-19; adult multi-system inflammatory disease, COVID-19 related; multi-system inflammatory disease, adult, COVID-19 related; multi-system inflammatory syndrome in adults associated with COVID-19; multisystem inflammatory disease, adult, COVID-19 related; multisystem inflammatory syndrome in adults associated with COVID-19

Networked: 90 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Thyroiditis
2.	Pleural Effusion (Pleural Effusions)
3.	Multiple Organ Failure (MODS)
4.	Hypotension (Low Blood Pressure)
5.	Ovarian Neoplasms (Ovarian Cancer)

Experts

1.	Donahoe, Patricia K: 5 articles (03/2010 - 01/2005)
2.	MacLaughlin, David T: 4 articles (03/2010 - 01/2005)
3.	Pieretti-Vanmarcke, Rafael: 2 articles (03/2010 - 11/2006)
4.	Teixeira, Jose: 2 articles (03/2010 - 12/2003)
5.	Gupta, Vandana: 2 articles (03/2007 - 10/2006)
6.	Kawakubo, Hirofumi: 2 articles (03/2007 - 10/2006)
7.	Maheswaran, Shyamala: 2 articles (03/2007 - 10/2006)
8.	Yeo, Giminna: 2 articles (03/2007 - 10/2006)
9.	Donahoe, P K: 2 articles (11/2000 - 09/2000)
10.	Ha, T U: 2 articles (11/2000 - 09/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to COVID-19 related adult multisystem inflammatory disease:

1.	Adrenal Cortex Hormones (Corticosteroids)IBA 01/01/2021 - "A presumptive diagnosis of MIS-A was made and treatment with corticosteroids was introduced with improvement. " 02/01/2022 - "It appears reasonable to treat the patient with fulminant myocarditis in SARS-CoV-2-associated MIS-A with high-dose corticosteroid "pulse" therapy in order to suppress the inflammatory response and MCS to correct initial metabolic derangement and reestablish/maintain vital organ perfusion. " 05/10/2022 - "We present a case of MIS-A in a woman in her 60s who had severe hypotension, progressive dyspnoea, massive pleural effusion, hypoxaemia, thyroiditis and multiple organ failure, which dramatically improved after treatment with corticosteroid and interleukin 6 inhibitor." 01/01/2023 - "The appropriate treatment for MIS-A remains unclear; anti-inflammatory agents, including intravenous immunoglobulin and corticosteroids, are commonly used. "
2.	Interleukin-6 (Interleukin 6)IBA 05/10/2022 - "We present a case of MIS-A in a woman in her 60s who had severe hypotension, progressive dyspnoea, massive pleural effusion, hypoxaemia, thyroiditis and multiple organ failure, which dramatically improved after treatment with corticosteroid and interleukin 6 inhibitor." 02/01/2022 - "Our patient had increased levels of D-dimer, fibrinogen, interleukin 6 (IL-6), and large artery thromboembolism, A positive direct Coomb's test was also more suggestive of immune-mediated hemolysis rather than traction hemolysis, which is the pathophysiology of hemolytic anemia in TTP. Furthermore, MIS-A is known to present with gastrointestinal (GI) symptoms, whereas our case reports predominantly neurological symptoms with relative GI sparing. " 06/01/2004 - "We examined the utility of 10 markers of MICS as predictors of prospective mortality and hospitalization, which included malnutrition-inflammation score (MIS), a fully quantitative score adopted from subjective global assessment, and serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), albumin, pre-albumin, total iron binding capacity, creatinine, total cholesterol and normalized protein nitrogen appearance. "
3.	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 06/28/2021 - "To our knowledge, this is the first report of the successful use of anakinra for MIS-A, a drug that has already proven useful in the treatment of refractive cases of MIS-C. " 06/28/2021 - "Anakinra may also play a pivotal role for the treatment of MIS-A." 06/28/2021 - "In this report, we detail the clinical picture and the diagnostic process that led to the diagnosis of MIS-A in a 27-year-old man, focusing on its treatment with anakinra and glucocorticoids, which resulted in full recovery. " 06/28/2021 - "Multisystem Inflammatory Syndrome in an Adult (MIS-A) Successfully Treated with Anakinra and Glucocorticoids."
4.	AnticoagulantsIBA 01/01/2021 - "She was diagnosed in an early stage of MIS-A and treated successfully with immune suppression, antiaggregants and anticoagulants. "
5.	Anti-Mullerian HormoneIBA 09/01/2003 - "The expression of Mullerian inhibiting substance (MIS), a key molecule in sex differentiation and reproduction, is tightly regulated. " 10/01/1985 - "Mullerian Inhibiting Substance (MIS), a fetal testicular product that causes regression of the Mullerian duct in the male mammalian embryo, was evaluated for its antitumor effect on the premise that a substance active against this genital precursor in the fetus might also be active against tumors derived from these tissues. " 05/01/1982 - "Mullerian inhibiting substance (MIS), a fetal testicular product which causes regression of the Mullerian duct in the male mammalian embryo, is being evaluated as an inhibitor of genital tract tumors. " 10/01/2006 - "Mullerian inhibiting substance (MIS), a member of the TGFbeta superfamily, causes regression of the Mullerian duct in male embryos. " 04/01/1992 - "Mullerian inhibiting substance (MIS), a testicular glycoprotein also known as anti-Mullerian hormone, plays a key role in male sexual development by causing regression of the Mullerian duct, the anlagen of the uterus, the Fallopian tubes, and part of the vagina. "
6.	Transforming Growth Factor beta (TGF-beta)IBA 11/24/2000 - "Müllerian inhibiting substance (MIS), a transforming growth factor-beta family member, causes regression of the Müllerian duct in male embryos. " 09/15/2000 - "Müllerian inhibiting substance (MIS), a member of the transforming growth factor-beta superfamily, induces regression of the Müllerian duct in male embryos. " 10/01/2006 - "Mullerian inhibiting substance (MIS), a member of the TGFbeta superfamily, causes regression of the Mullerian duct in male embryos. " 06/01/1999 - "Müllerian-inhibiting substance (MIS), a gonadal hormone in the transforming growth factor-beta superfamily, induces Müllerian duct involution during male sexual differentiation. " 07/23/1996 - "During male gonadal development Müllerian duct regression is mediated by the actions of the hormone Müllerian inhibiting substance (MIS), a member of the transforming growth factor beta superfamily. "
7.	MisonidazoleIBA 01/01/1990 - "The anal and oral administration routes were compared in 40 rats to study the distribution of misonidazole (MIS), a radiation sensitizer, in the serum, uterus and vagina. " 09/01/1988 - "Fourteen patients with far-advanced gastric cancer were treated surgically followed by intraperitoneal hyperthermic perfusion (IPHP) with mitomycin C (MMC) and misonidazole (MIS), a thermosensitizing drug. " 07/01/1988 - "Fifteen patients with far-advanced gastric cancer were given surgical treatment followed by intraperitoneal hyperthermic perfusion (IPHP) with mitomycin C (MMC) and misonidazole (MIS), a thermosensitizing drug. " 08/01/1984 - "Treatment of mice (some bearing Lewis Lung tumors), with penicillin (PEN) at 500 mg/l drinking water for one week prior to treatment with misonidazole (MIS), resulted in: the elimination of their anaerobic cecal flora; a decrease in MIS-induced neurotoxicity; an increase in pharmacological exposure to MIS; a decrease in MIS chemopotentiation; a probable increase in MIS radiosensitization; an increase in MIS induced hypothermia. "
8.	anti-Mullerian hormone receptorIBA 11/14/2006 - "Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. " 03/01/2010 - "Mullerian Inhibiting Substance (MIS), a member of the TGF-beta family, causes regression of the Mullerian duct in male embryos, after binding to Mullerian Inhibiting Substance Receptor II (MISRII). "
9.	Estrogen Receptor betaIBA 09/01/2007 - "In the present study, we demonstrate that treatment of the genetic females with anti-estrogen (tamoxifen) leads to their masculinization, suppresses P450arom mRNA expression, and induces mRNA expression of Müllerian inhibiting substance (MIS), a member of the transforming growth factor-beta (TGF-beta) superfamily, while it has no effect on mRNAs expression of estrogen receptor-alpha (ERalpha) and ERbeta. "
10.	Estrogen Receptor alphaIBA 09/01/2007 - "In the present study, we demonstrate that treatment of the genetic females with anti-estrogen (tamoxifen) leads to their masculinization, suppresses P450arom mRNA expression, and induces mRNA expression of Müllerian inhibiting substance (MIS), a member of the transforming growth factor-beta (TGF-beta) superfamily, while it has no effect on mRNAs expression of estrogen receptor-alpha (ERalpha) and ERbeta. "

Therapies and Procedures

1.	Aftercare (After-Treatment) 05/10/2022 - "We present a case of MIS-A in a woman in her 60s who had severe hypotension, progressive dyspnoea, massive pleural effusion, hypoxaemia, thyroiditis and multiple organ failure, which dramatically improved after treatment with corticosteroid and interleukin 6 inhibitor."
2.	Oral Administration 01/01/1990 - "The anal and oral administration routes were compared in 40 rats to study the distribution of misonidazole (MIS), a radiation sensitizer, in the serum, uterus and vagina. "
3.	Therapeutics 10/29/2021 - "In our case, EMB facilitated identification of MIS-A and guided therapy. " 10/11/2021 - "Therefore, patients with MIS-A may respond to supportive therapies that control hyperinflammation. " 01/01/2021 - "We describe 2 diagnostically challenging cases of SARS-CoV-2 and Multi-Inflammatory Syndrome-Adult (MIS-A), in patients with a history of acute lymphoblastic leukemia following cellular therapy administration and review evolving characterization of both the natural course of SARS-CoV-2 infection and toxicities experienced in younger cancer immunotherapy patients. " 09/01/2023 - "She was tentatively diagnosed with multisystem inflammatory syndrome in adults (MIS-A) and received steroid pulse therapy. " 12/01/2021 - "In addition to supportive management, adjunctive therapies such as IVIG may be efficacious in MIS-A and should be further investigated."
4.	Minimally Invasive Surgical Procedures 07/01/2021 - "Visual symptoms, Neck/shoulder problems and associated factors among surgeons performing Minimally Invasive Surgeries (MIS): A comprehensive survey." 01/01/2010 - "In minimally invasive surgery (MIS), a surgeon needs to acquire a certain level of basic psychomotor MIS skills to perform surgery safely. " 08/01/2009 - "Despite the complexities of minimally invasive surgery (MIS), a Canadian approach to training surgeons in this field does not exist. " 06/01/2009 - "With minimally invasive surgery (MIS), a man-machine environment was brought into the operating room, which created mental and physical challenges for the operating team. " 01/01/2000 - "With the advent of minimally invasive surgery (MIS) a decade ago, the requirements for operating rooms (OR) and their equipment have been increased. "
5.	Extracorporeal Membrane Oxygenation 03/07/2022 - "Multisystem inflammatory syndrome in adults (MIS-A) following COVID-19 requiring venoarterial extracorporeal membrane oxygenation." 01/01/2022 - "MIS-A- patients compared with MIS-A+ patients were characterized by a shorter delay between COVID-19 symptoms onset and myocarditis, a lower left ventricular ejection fraction, and a higher rate of in-ICU organ failure, and were more likely to require mechanical circulatory support with venoarterial extracorporeal membrane oxygenation (92% vs 16%; P < 0.0001). "